drugset / Trial / NCT04305691

Trial of Ixazomib for Kaposi Sarcoma

NCT04305691

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2023-11-07
Primary completion
2029-03-15
Completion
2029-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Ixazomib Unknown Oral

Indications